Anne‐Marie Martin - Concepedia

Author

Anne‐Marie Martin

Also Known As

, A. Martin, A.-M. Martin, A.M. Martin A.M. Martin, A.‐M. Martin, AM Martin, Ann-Marie Martin, Anne Marie Martin, Anne-Marie Martin, Anne-Marie Martin (389995)

184

Publications

6.7K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)University College Cork Memorial Sloan Kettering Cancer Center Research Triangle Park Foundation University of Pennsylvania

About

Anne‐Marie Martin is an author at GlaxoSmithKline (United States) specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	616
2	Health Sciences	3	3	75
3	Engineering	1	1	158
4	Nursing	1	1	51
5	Public Health	1	1	37

Anne‐Marie Martin

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Keith T. Flaherty, Caroline Robert, Peter Hersey, New England Journal of Medicine	2012	2.1K
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, New England Journal of Medicine	2014	1.8K
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL Li Liu, James Greger, Hong Shi, Cancer Research	2009	471
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer Manish A. Shah, Zev A. Wainberg, Daniel V.T. Catenacci, PLoS ONE	2013	204
Correlation of <i>BRAF</i> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials Ademi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, Clinical Cancer Research	2015	201
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) Katherine L. Nathanson, Anne‐Marie Martin, Bradley Wubbenhorst, Clinical Cancer Research	2013	183
Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma Jessie Villanueva, Jeffrey R. Infante, Clemens Krepler, Cell Reports	2013	180
Association of HPC2/ELAC2 Genotypes and Prostate Cancer Timothy R. Rebbeck, A. H. C. Walker, Charnita Zeigler‐Johnson, The American Journal of Human Genetics Hpc2/elac2 GenotypesUrologyProstatic DiseaseCancer GeneticsMedicine	2000	158
Screening for Genomic Rearrangements in Families with Breast and Ovarian Cancer Identifies BRCA1 Mutations Previously Missed by Conformation-Sensitive Gel Electrophoresis or Sequencing Meredith A. Unger, Katherine L. Nathanson, Danielle Antin‐Ozerkis, The American Journal of Human Genetics EngineeringSomatic VariantTumor HeterogeneityMedicineGenetics	2000	158
Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial Connie Wong, Jason Baum, Angela Silvestro, Cancer Research	2020	96

Page 1